When a dog is lost behind pain:

Find them with LIAVIUM™-CA1

LIAVIUM-CA1 (pregabalin chewable tablets) is the first and only FDA conditionally approved pregabalin for the management of pain and clinical signs associated with Chiari-like malformation (CM) and syringomyelia (SM) in dogs.

Want to Know More?

The missing piece in pain management

Pregabalin has long been the standard for managing neuropathic pain in humans. LIAVIUM-CA1 finally brings the proven science and relief to dogs.
Pill_Bottles_1X

Pregabalin dosed for dogs

30 mg
90 mg
180 mg

With a 6-7 hour elimination half life, LIAVIUM-CA1 is dosed only twice a day. This means there is less likelihood of breakthrough pain, and a potentially better therapeutic outcome.
Predictable

No compounding needed—FDA oversight ensures every dose meets quality standards.
Potent

High potency and rapid absorption work together to powerfully block pain signals.
Consistent

Twice-daily dosing maintains around-the-clock pain relief. No wearing off between doses—just steady comfort.

Pregabalin vs. Gabapentin

A review of human studies found that pregabalin provided faster and better relief of neuropathic pain than gabapentin, with fewer days of severe pain and fewer side effects.1
Characteristic Pregabalin Gabapentin
Approved formulation in dogs
Yes
No
Oral bioavailability  
90% bioavailability 
27–60% bioavailability 
Absorption
Consistent and independent of dose and frequency 
Variable —  lower at higher doses 
Mechanism of Action 
Binds to α2δ subunit of voltage gated calcium channels 
Binds to α2δ subunit of voltage gated calcium channels 
Potency2
6–10x more potent
Less potent antinociceptive agent
Half-life2-4
6-7 hours
3-4 hours
Dosing 
Twice daily 
Three times daily